Viragen, Inc.

PLANTATION, Fla., March 27 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA - News) and its majority-owned subsidiary, Viragen International, Inc. (OTC Bulletin Board: VGNI - News), today announced that Acta Oncologica, a leading journal in clinical oncology, has accepted to publish an article profiling Multiferon® (multi-subtype, natural human alpha interferon) in the adjuvant treatment of high-risk (Stages IIb-III) malignant melanoma.

Comment - It's good to see that this data has been accepted fo publishing by a respected journal. I would love to know much more about the p value, how many patients etc. I guess we'll just wait for the article.